MRK - Merck & Co., Inc.
After hours:
| Previous Close | 112.30 |
| Open | 112.00 |
| Bid | 111.00 x 800 |
| Ask | 117.50 x 900 |
| Day's Range | 110.65 - 113.19 |
| 52 Week Range | 83.05 - 119.65 |
| Volume | |
| Avg. Volume | 7,384,817 |
| Market Cap | 281.833B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 21.69 |
| EPS (TTM) | 5.12 |
| Earnings Date | Aug 01, 2023 |
| Forward Dividend & Yield | 2.92 (2.63%) |
| Ex-Dividend Date | Jun 14, 2023 |
| 1y Target Est | 124.21 |
Business WireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
RAHWAY, N.J. & NUTLEY, N.J., May 25, 2023--KEYTRUDA® Plus LENVIMA® Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Business WireMerck Announces Third-Quarter 2023 Dividend
RAHWAY, N.J., May 23, 2023--Merck Announces Third-Quarter 2023 Dividend
Yahoo Finance VideoFed, labor market concerns showing 'some dents in the armor of the consumer': Strategist
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.
BloombergDrugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data
(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.Most Read from BloombergHere’s How Much Wealth You Need to Join the Richest 1% GloballyMercedes Sets Out to Make Sexy Vans With Yacht-Like InteriorsJPMorgan Asset Says Markets Are Right to Bet on US Rate CutsDebt-Limit Talks to Intensify as Biden Set to Depart for JapanSeveral major drugmakers keen to expand in immunology have been studying the $23 bi
Business WireMerck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
RAHWAY, N.J., May 15, 2023--Merck ASCO Curtain Raiser
ZacksThe Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International
UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International are part of the Zacks top Analyst Blog.
ZacksTop Research Reports for UnitedHealth Group, Merck & Texas Instruments
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Merck & Co., Inc. (MRK) and Texas Instruments Incorporated (TXN).
Yahoo Finance UKUS stocks and FTSE 100 lower as BoE hikes rates again
Investors are gearing up for an announcement on UK interest rates which is due at noon.
ACCESSWIREMerck Announces Global Grants Program To Improve Access to Quality Health Care in Underserved Communities
To support the work of nonprofits dedicated to improving the well-being of underserved populations in communities around the world, Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has announced a new global grants program, Solutions for Healthy Communities (SHC).
ZacksModerna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
ZacksHere is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
- Reuters
Moderna beats COVID vaccine sales expectations as deferred revenue rolls in
Moderna Inc on Thursday reported stronger-than-expected sales of $1.9 billion for its COVID-19 vaccine in the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023 sales expectations unchanged. The vaccine maker posted a profit of 19 cents per share, compared with analyst expectations for a loss of $1.77 per share, in part because sales were higher than expected. Moderna said it continued to expect COVID vaccine sales of $5 billion for the year based on advance purchase agreements.
Business WireMerck to Participate in Bank of America Securities 2023 Healthcare Conference
RAHWAY, N.J., May 03, 2023--Merck to Participate in Bank of America Securities 2023 Healthcare Conference
- Reuters
CORRECTED-UPDATE 2-US FDA panel backs restricted use of AstraZeneca's prostate cancer drug (April 28)
A panel of U.S. Food and Drug Administration advisers on Friday voted for the restricted use of British drugmaker AstraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer. The FDA panel voted 11-1 with one abstention, in favor of Lynparza, in combination with other medications – abiraterone and prednisone or prednisolone – as a first-line treatment for a type of treatment-resistant prostate cancer in adult patients. Its recommendation comes after Lynparza and similar class of therapies suffered a series of safety setbacks as clinical data suggested that patients do not live as long as those given chemotherapy when given as a second-line therapy.
- Reuters
CORRECTED-US FDA panel backs AstraZeneca's prostate cancer drug (April 28)
A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AstraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer. The FDA panel voted 11-1 with one abstention, in favor of using the drug, Lynparza, in combination with other medications – abiraterone and prednisone or prednisolone – to treat a type of treatment-resistant prostate cancer in adult patients.
Business WireUpdate on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
RAHWAY, N.J., April 28, 2023--Update on FDA Advisory Committee Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line mCRPC
Motley FoolMerck (MRK) Q1 2023 Earnings Call Transcript
Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dr. Dean Li, president of Merck Research Labs. Before we get started, I'd like to point out a few items.
ZacksPharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.
ZacksMerck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View
Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Yahoo Finance VideoDrugmakers brace for serious headwinds ahead
Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.
ReutersDrugmakers scout for deals, ramp up research spending
Drugmakers including Merck & Co, AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue. Several top drugs such as AbbVie flagship Humira have begun to face competition from new rivals or are expected to lose patent protections in the next few years, and deals could be a quick fix to address the loss of revenue from older therapies. Merck recently announced a $10.8 billion deal to buy Prometheus Biosciences Inc.
Motley Fool2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back
The stock market has immersed itself in the financial reports that hundreds of companies are releasing. After having seen pressure throughout much of this week, investors got themselves in a better mood on Thursday morning. Futures contracts signaled a potential triple-digit rise in the Dow Jones Industrial Average (DJINDICES: ^DJI).
